LLRAPC Newsletter – July 2026(459 KB) - LMSG/LLR APC newsletters
Date added: 6th Aug 2026
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| ACAMPROSATE | Yellow | Alcohol dependence |
There is currently no commissioned service within general practice to support the prescribing and ongoing management of this treatment. There are, though, potential clinical benefits in the maintenance of abstinence from alcohol (and these patients are likely to have been discharged from specialist services as they are no longer drinking alcohol), so where a clinician has the appropriate expertise and feels clinically competent to do so, they may choose to prescribe. However, there is no contractual requirement or expectation for GPs to initiate or continue prescribing, and practices are not obligated to issue these prescriptions. |
| CENOBAMATE (Ontozry®) (UPDATED) | Yellow | Focal onset seizures in epilepsy |
In line with NICE TA753 |
| DULAGLUTIDE (Trulicity®) | Green | Type 2 diabetes |
Conditional on prescriber being trained to select and train patients – use in conjunction with updated NICE NG28. Once a week preparation. |
| LOTEPREDNOL ETABONATE eye drops (Lotemax®) (UPDATED) | Yellow | Ophthalmic inflammatory conditions |
Ophthalmic inflammatory conditions needing topical steroid where standard drops have caused, or may cause, raised intraocular pressure (IOP). |
| NALTREXONE (UPDATED) | Yellow | For use in opioid dependency |
To be initiated and managed by specialists for maintenance treatment to help prevent relapse in opioid dependence in line with NICE TA 115. There is currently no commissioned service within general practice to support the prescribing and ongoing management of this treatment. Naltrexone may provide clinical benefit as a maintenance treatment to help prevent relapse in opioid dependence, so where a clinician has the appropriate expertise and feels clinically competent to do so, they may choose to prescribe. However, there is no contractual requirement or expectation for GPs to initiate or continue prescribing, and practices are not obligated to issue these prescriptions.
|
| Relugolix (Orgovyx®) (UPDATED) | Yellow | For treating hormone sensitive prostate cancer |
|
| SEMAGLUTIDE (Rybelsus®) | Green | Type 2 diabetes |
In line with NICE NG28 |
Other Updates on this Website
Recent documents from LLR APC and TAS
Patient choice for dispensing of continence and stoma appliances(143 KB)
Date added: 5th Aug 2026
Adult AIR Asthma Action Plan(363 KB)
Date added: 12th Jul 2026
Adult MART Asthma Action Plan(306 KB)
Date added: 12th Jul 2026
Adult Asthma Action Plan(301 KB)
Date added: 12th Jul 2026
Guidelines for the Management of Catheterised Patients in the Community(350 KB) - Guidelines
Date added: 19th Apr 2017
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more